{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:03:59Z","timestamp":1790085839963,"version":"4.0.1"},"reference-count":13,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe real\u2010world patterns of use, virologic and immunologic outcomes and treatment persistence among people with HIV (PWH) initiating fostemsavir (FTR) in a diverse US cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study of adults receiving FTR in clinical practice, stratified by baseline viral suppression status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Adults with \u22651 FTR prescription between July 2020 and August 2023 were included and followed for 12\u2009months. Individuals with trial participation were excluded. Outcomes included virologic suppression (&lt;50 and &lt;200 copies\/mL), confirmed virologic failure, viral blips, CD4 changes and immunologic recovery among those with baseline CD4 &lt;350 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      . Persistence and adherence were assessed using dispensing data and proportion of days covered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy\u2010seven PWH were included (60% viremic, 40% suppressed). Multidrug resistance was observed in a subset (31%). At 12\u2009months, most individuals remained on FTR, with high adherence among the subset with available dispensing data. Among viremic initiators, a minority achieved viral suppression, though reductions in viral load were observed. Among suppressed initiators, most maintained suppression. CD4 counts increased in both subgroups, with greater gains among those suppressed at initiation. Modifications to optimized background therapy were infrequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real\u2010world, diverse cohort, FTR was well tolerated, with high persistence and, in the dispensing\u2010data subset, high adherence. It effectively maintained viral suppression among suppressed individuals and provided immunologic benefits across subgroups, including viremic initiators. These findings support FTR as a valuable treatment option for heavily treatment\u2010experienced PWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70303","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:31:11Z","timestamp":1790083871000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real\u2010world use and effectiveness of fostemsavir in a\n                    <scp>US<\/scp>\n                    clinical setting: Insights from Trio Health\n                    <scp>HIV<\/scp>\n                    Research Network"],"prefix":"10.1111","author":[{"given":"Richard","family":"Elion","sequence":"first","affiliation":[{"name":"Analytics Trio Health  Louisville Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4566-1174","authenticated-orcid":false,"given":"Cassidy","family":"Henegar","sequence":"additional","affiliation":[{"name":"Epidemiology and Real World Evidence Viiv Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2245-3507","authenticated-orcid":false,"given":"Isobel","family":"McEwen","sequence":"additional","affiliation":[{"name":"Analytics Trio Health  Louisville Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-9382","authenticated-orcid":false,"given":"Andrew","family":"Frick","sequence":"additional","affiliation":[{"name":"Analytics Trio Health  Louisville Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-1976","authenticated-orcid":false,"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Infectious Disease Midway Immunology and Research Center  Fort Pierce Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Santiago","sequence":"additional","affiliation":[{"name":"Care Resource  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karam","family":"Mounzer","sequence":"additional","affiliation":[{"name":"School of Medicine at the University of Pennsylvania Philadelphia Fight Community Health Centers  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Huhn","sequence":"additional","affiliation":[{"name":"Ruth M. Rothstein CORE Center Rush University Medical Center  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Walworth","sequence":"additional","affiliation":[{"name":"Medical Affairs and Education Labcorp  Burlington North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Ragone","sequence":"additional","affiliation":[{"name":"Epidemiology and Real World Evidence Viiv Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-9689","authenticated-orcid":false,"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[{"name":"Epidemiology and Real World Evidence Viiv Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30240-X"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010023\u201000870\u20106"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09122-5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/505356"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.10.1129"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13700"},{"key":"e_1_2_10_9_1","unstructured":"TorkjaziG GalliL GagliardiniR et al.Efficacy and durability of fostemsavir ibalizumab or lenacapavir\u2010including regimens in people living with multidrug\u2010resistant HIV\u20101: results from the PRESTIGIO registry. Poster Presentation presented at: European Aids Conference; October 18 2023; Warsaw Poland."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13650"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106252"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab583"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/20499361251325103"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.01.023"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70303","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:31:13Z","timestamp":1790083873000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":13,"alternative-id":["10.1111\/hiv.70303"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70303","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"2026-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hiv.70303"}}